

# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 30, NUMBER 6

JUNE 2009

## ORIGINAL ARTICLES

- 507 **Comparison of the Efficacy of a Hydrogen Peroxide Dry-Mist Disinfection System and Sodium Hypochlorite Solution for Eradication of *Clostridium difficile* Spores** • F. Barbut, PharmD, PhD; D. Menuet, BSc; M. Verachten, BSc; E. Girou, PharmD
- 515 **Commentary: New Approaches to Decontamination of Rooms After Patients Are Discharged** • John M. Boyce, MD
- 518 **Multicenter Study of the Impact of Community-Onset *Clostridium difficile* Infection on Surveillance for *C. difficile* Infection** • Erik R. Dubberke, MD, MSPH; Anne M. Butler, MS; Bala Hota, MD, MPH; Yosef M. Khan, MBBS, MPH; Julie E. Mangino, MD; Jeanmarie Mayer, MD; Kyle J. Popovich, MD; Kurt B. Stevenson, MD, MPH; Deborah S. Yokoe, MD, MPH; L. Clifford McDonald, MD; John Jernigan, MD, MS; Victoria J. Fraser, MD; Prevention Epicenters Program from the Centers for Disease Control and Prevention
- 526 ***Clostridium difficile* Infection in Ohio Hospitals and Nursing Homes During 2006** • Robert J. Campbell, PhD; Lynn Giljahn, MPH; Kim Machesky, MPH; Katie Cibulskas-White, BS; Lisa M. Lane, MS; Kyle Porter, MAS; John O. Paulson, MS; Forrest W. Smith, MD; L. Clifford McDonald, MD
- 534 **Prospective Evaluation of Colonization with Extended-Spectrum  $\beta$ -Lactamase (ESBL)-Producing Enterobacteriaceae Among Patients at Hospital Admission and of Subsequent Colonization with ESBL-Producing Enterobacteriaceae Among Patients During Hospitalization** • Reuven Friedmann, MD; David Raveh, MD; Esther Zartzer, MD; Bernard Rudensky, PhD; Ellen Broide, BSc; Denise Attias, BSc; Amos M. Yinnon, MD
- 543 **High Frequency of Multidrug-Resistant Gram-Negative Rods in 2 Neonatal Intensive Care Units in the Philippines** • Jennifer M. Litzow, MD, MPH; Christopher J. Gill, MD; Jose B. V. Mantaring, MD, MPH; Matthew P. Fox, PhD, MPH; William B. MacLeod, DSc; Myrna Mendoza, MS; Sookee Mendoza, MD; Rebecca Scobie, BS; Charles W. Huskins, MD; Donald A. Goldman, MD; David H. Hamer, MD
- 550 **Outbreak of *Pseudomonas aeruginosa* Infection Associated With Contamination of a Flexible Bronchoscope** • Carlos A. DiazGranados, MD; Marolyn Y. Jones, RN; Thiphassone Kongphet-Tran, BS; Nancy White, RN; Mark Shapiro, MS; Yun F. Wang, PhD; Susan M. Ray, MD; Henry M. Blumberg, MD
- 556 **Association Between Physician Caseload and Patient Outcome for Sepsis Treatment** • Chao-Hung Chen, MD, MPH; Yi-Hua Chen, PhD; Hsiu-Chen Lin, MD; Heng-Ching Lin, PhD
- 563 **Validation of a Modified Version of the National Nosocomial Infections Surveillance System Risk Index for Health Services Research** • Nick Daneman, MD, FRCPC; Andrew E. Simor, MD, FRCPC; Donald A. Redelmeier, MD, FRCPC, FACP

## CONCISE COMMUNICATIONS

- 570 **Limitations of the Efficacy of Surface Disinfection in the Healthcare Setting** • Gareth J. Williams, PhD; Stephen P. Denyer, FRPharmS; Ian K. Hosein, MD; Dylan W. Hill, BSc; Jean-Yves Maillard, PhD



THE OFFICIAL JOURNAL OF THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

CONTENTS CONTINUED INSIDE

**Kills 99.99%** or more  
of infection causing pathogens

*Maximus introduces*

**Max  
Guard™**  
*with antimicrobial protection*





# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 30, NUMBER 6

JUNE 2009

CONTENTS CONTINUED FROM COVER

- 574 Feasibility of Routinely Using Hydrogen Peroxide Vapor to Decontaminate Rooms in a Busy United States Hospital** • Jonathan A. Otter, BSc; Matthew Puchowicz, BS; David Ryan, BS; James A. G. Salkeld, BEng; Timothea A. Cooper, RN; Nancy L. Havill, MT; Kathy Tuozzo, MSN; John M. Boyce, MD
- 578 Self-Protection as a Driver for Hand Hygiene Among Healthcare Workers** • Michael A. Borg, MD; Mohamed Benbachir, PhD; Barry D. Cookson, MD; Saida Ben Redjeb, PhD; Ziad Elnasser, PhD; Ossama Rasslan, PhD; Deniz Gür, PhD; Ziad Daoud, PhD; Despo Pieridou Bagatzouni, PhD
- 581 Rate of Latent Tuberculosis Infection Detected by Occupational Health Screening of Nurses New to a London Teaching Hospital** • Priya Khanna, MD; Vladyslav Nikolayevskyy, PhD; Fiona Warburton; Elek Dobson, BSc; Francis Drobniowski, MD, PhD
- 585 Evidence of Vaccine Protection Among Thai Medical Students and Implications for Occupational Health** • Panudda Srichomkwun, MD; Anucha Apisarnthanarak, MD; Kanokporn Thongphubeth, RN; Chananart Yuekyen, RN; Linda M. Mundy, MD
- 589 Response to an Education Program for Parents About Adult Pertussis Vaccination** • Pui-Ying Iroh Tam, MD; Paul Visintainer, PhD; Donna Fisher, MD
- 593 Epidemiologic Investigation of a 2007 Outbreak of *Serratia marcescens* Bloodstream Infection in Texas Caused by Contamination of Syringes Prefilled With Heparin and Saline** • John R. Su, MD, PhD, MPH; David B. Blossom, MD; Wendy Chung, MD; Jessica Smartt Gullion, PhD; Neil Pascoe, BSN, RN; Gary Heseltine, MD, MPH; Arjun Srinivasan, MD, MPH
- 596 Does an Educational Session With an Infectious Diseases Physician Reduce the Use of Inappropriate Antibiotic Therapy for Inpatients With Positive Urine Culture Results? A Controlled Before-and-After Study** • Patricia Pavese, MD; Nathalie Saurel, PharmD; José Labarère, MD; Corinne Decouchon, MD; Jean-Philippe Vittoz, BSc; Luc Foroni, PharmD; Max Maurin, MD, PhD; Patrice François, MD, PhD
- 600 Trends in Antibacterial Use in Hospitalized Pediatric Patients in United States Academic Health Centers** • Amy L. Pakyz, PharmD; Holly E. Gurgle, BS; Omar M. Ibrahim, BS; Michael J. Oinonen, PharmD; Ronald E. Polk, PharmD

## RESEARCH BRIEFS

- 604 Evaluation of Rapid Culture Screening Assay for Methicillin-Resistant *Staphylococcus aureus* (MRSA) for Detection of Environmental MRSA Contamination** • O. Sherlock, PhD; N. O'Connell, BSc; E. Creamer, MsC; S. O'Hara; H. Humphreys, MD
- 606 One-Day Point-Prevalence Survey of Central, Arterial, and Peripheral Line Use in Adult Inpatients** • Katherine A. Voges, BS; Douglas Webb, MD; Lauren L. Fish, RN; Amy B. Kressel, MD

## LETTER TO THE EDITOR

- 609 Difficulty in Diagnosing Surgical Site Infection After Arthroscopy in Developing Countries** • Anucha Apisarnthanarak, MD; Siriporn Wittayachanyapong, MD; Pranee Sitaposa, MD; Kanokporn Thongphubeth, RN; Hilary Babcock, MD; Victoria J. Fraser, MD

*An Official Publication of the Society for Healthcare Epidemiology of America*

**EDITOR**

Suzanne F. Bradley, MD • Ann Arbor, MI

**DEPUTY EDITOR**

Carol A. Kauffman, MD • Ann Arbor, MI

**SENIOR ASSOCIATE EDITORS**

C. Glen Mayhall, MD • Galveston, TX  
Gina Pugliese, RN, MS • Chicago, IL  
William Schaffner, MD • Nashville, TN

**ASSOCIATE EDITORS**

Ebbing Lautenbach, MD, MPH • Philadelphia, PA  
Preeti N. Malani, MD, MSJ • Ann Arbor, MI  
David Weber, MD, MPH • Chapel Hill, NC

**STATISTICS CONSULTANT**

Rodney L. Dunn, MS • Ann Arbor, MI

**SECTION EDITOR FOR GUIDELINES,  
POSITION PAPERS, AND INVITED REVIEWS**

Carol Chenoweth, MD • Ann Arbor, MI

**MANAGING EDITOR**

Gordon Rudy • Chicago, IL

**PAST EDITORS**

*Infection Control*

Richard P. Wenzel, MD, 1980–1990 (vols. 1–11)

*Infection Control and Hospital Epidemiology*

Richard P. Wenzel, MD, 1991–1992 (vols. 12 and 13)

Michael D. Decker, MD, 1993–2001 (vols. 14–22)

Barry M. Farr, MD, 2002–2004 (vols. 23–25)

William R. Jarvis, MD, 2005–2006 (vols. 26 and 27)

**EDITORIAL ADVISORY BOARD**

Miriam Alter, PhD, MD • Atlanta, GA  
Anucha Apisarnthanarak, MD • Pratumthani, Thailand  
Lennox Archibald, MD, FRCP • Alachua, FL  
Hilary Babcock, MD • St. Louis, MO  
Elise M. Beltrami, MD, MPH • Decatur, GA  
David Birnbaum, PhD, MPH • Sidney, BC  
Christian Brun-Buisson, MD • Creteil, France  
John P. Burke, MD • Salt Lake City, UT  
David P. Calfee, MD, MS • New York, NY  
Yehuda Carmeli, MD, MPH • Tel Aviv, Israel  
Sara E. Cosgrove, MD, MS • Baltimore, MD  
Donald E. Craven, MD • Burlington, MA  
Burke A. Cunha, MD • Mineola, NY  
Erika D'Agata, MD, MPH • Boston, MA  
Patch Dellinger, MD • Seattle, WA  
Daniel Diekema, MD • Iowa City, IA  
Charles E. Edmiston, Jr., PhD • Milwaukee, WI  
Theodore C. Eickhoff, MD • Denver, CO  
Martin S. Favero, PhD • Irvine, CA  
Jon P. Furuno, PhD • Baltimore, MD  
Richard A. Garibaldi, MD • Farmington, CT  
Petra Gastmeier, MD • Hanover, Germany  
Dale N. Gerding, MD • Hines, IL  
Donald A. Goldmann, MD • Boston, MA  
Donna Haiduvén, RN, PhD, CIC • Tampa, FL  
Anthony D. Harris, MD, MPH • Baltimore, MD  
David K. Henderson, MD • Bethesda, MD  
Loreen A. Herwaldt, MD • Iowa City, IA  
Peter N. R. Heseltine, MD • San Juan, CA  
Karen Hoffmann, RN, PhD, CIC, MS • Chapel Hill, NC  
Janine Jagger, MPH, PhD • Charlottesville, VA  
John A. Jernigan, MD, MS • Atlanta, GA  
James T. Lee, MD, PhD • St. Paul, MN  
L. Clifford McDonald, MD • Atlanta, GA

Allison McGeer, MD • Toronto, ON  
Leonard A. Mermel, DO, ScM • Providence, RI  
Robert R. Muder, MD • Pittsburgh, PA  
Carlene A. Muto, MD, MS • Pittsburgh, PA  
Joseph M. Mylotte, MD, CIC • Buffalo, NY  
David L. Paterson, MBBS, FRACP • Pittsburgh, PA  
Jan Evans Patterson, MD • San Antonio, TX  
Sindy M. Paul, MD • Yardley, PA  
David A. Pegues, MD • Los Angeles, CA  
Eli Perencevich, MD, MS • Baltimore, MD  
Michael A. Pfaller, MD • Iowa City, IA  
Didier Pittet, MD, MS • Geneva, Switzerland  
Gina Pugliese, RN, MS • Chicago, IL  
Isaam Raad, MD • Houston, TX  
Jordi Rello, MD, PhD • Tarragona, Spain  
Manfred L. Rotter, MD, DipBact • Vienna, Austria  
Henning Rüden, MD • Berlin, Germany  
William A. Rutala, PhD, MPH • Chapel Hill, NC  
Lisa Saiman, MD, MPH • New York, NY  
Sanjay Saint, MD, MPH • Ann Arbor, MI  
William E. Scheckler, MD • Madison, WI  
Lynne M. Schulster, PhD • Atlanta, GA  
John A. Sellick, DO • Amherst, NY  
Kent Sepkowitz, MD • New York, NY  
Samir Shah, MD, MSCE • Philadelphia, PA  
Andrew E. Simor, MD • Toronto, ON  
Philip W. Smith, MD • Omaha, NE  
Denis W. Spelman, MD • Prahan, Victoria, Australia  
Jeffrey R. Starke, MD • Houston, TX  
Janet E. Stout, PhD • Pittsburgh, PA  
Clyde Thornsberry, PhD • Franklin, TN  
William Trick, MD • Chicago, IL  
Antoni Trilla, MD, PhD • Barcelona, Spain  
Robert A. Weinstein, MD • Chicago, IL  
Andreas Widmer, MD, MS • Basel, Switzerland  
Marcus Zervos, MD • Royal Oak, MI

*Infection Control and Hospital Epidemiology* (ISSN 0899-823X) is published monthly by the University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637-2954 (<http://www.journals.uchicago.edu/ICHE/>). The editorial office is in Chicago, Illinois.

**Editorial Office**

Communications should be addressed to the Editor, *Infection Control and Hospital Epidemiology*, 1427 E. 60th St., Chicago, IL 60637-2954; (e-mail: [iche@press.uchicago.edu](mailto:iche@press.uchicago.edu)); telephone: 773-773-2298, fax: 773-753-4247). Contributors should consult the Information for Authors, which is available at the journal's Web site.

**Advertising**

Please direct advertising inquiries to Journals Advertising, University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637 (e-mail: [cbarhany@press.uchicago.edu](mailto:cbarhany@press.uchicago.edu); telephone: 773-702-8187; fax: 773-702-0172). Publication of an advertisement in *Infection Control and Hospital Epidemiology* does not imply endorsement of its claims by the Society for Healthcare Epidemiology of America, by the Editor, or by the University of Chicago. Correspondence regarding advertising should be addressed to the advertising office in Chicago.

**Permissions**

Articles may be copied or otherwise reused without permission only to the extent permitted by Sections 107 and 108 of the US Copyright Law. Permission to copy articles for personal, internal, classroom, or library use may be obtained from the Copyright Clearance Center (<http://www.copyright.com>). For all other uses, such as copying for general distribution,

for advertising or promotional purposes, for creating new collective works, or for resale, please contact the Permissions Coordinator, Journals Division, University of Chicago Press, 1427 E. 60th St., Chicago, IL 60637 (e-mail: [journalpermissions@press.uchicago.edu](mailto:journalpermissions@press.uchicago.edu); fax: 773-834-3489). Articles in the public domain may be used without permission, but it is customary to contact the author.

**Subscriptions**

Subscription rates for 2009 are \$171 for individuals and \$401 for institutions. Additional rates for non-US subscribers and reduced rates for fellows, residents, and students are available at <http://www.journals.uchicago.edu/ICHE>. Subscription agent for Japan: Kinokuniya Company, Ltd. Individuals have the option to order directly from the University of Chicago Press. Single copy rates: individuals \$18; institutions \$40.

Please direct subscription inquiries, requests for back issues, and address changes to Journals Division, University of Chicago Press, P.O. Box 37005, Chicago, IL 60637 (e-mail: [subscriptions@press.uchicago.edu](mailto:subscriptions@press.uchicago.edu); telephone: 773-753-3347 or toll-free in the United States and Canada 877-705-1878; fax: 773-753-0811 or toll-free 877-705-1879).

**Postmaster:** Send address changes to *Infection Control and Hospital Epidemiology*, University of Chicago Press, P.O. Box 37005, Chicago, IL 60637-2954.

Periodicals postage paid at Chicago, Illinois, and at an additional mailing office.

Published by the University of Chicago Press, Chicago, Illinois. © 2009 by the Society for Healthcare Epidemiology of America. All rights reserved. This publication is printed on acid-free paper.



# FIND THE MICROBE THAT COULD COST THIS PATIENT HER LIFE.

80% of the bacteria that cause infections reside in the first five layers of the patient's own skin! That's why there's ChloraPrep®. ChloraPrep combines the CDC-recommended formulation of 2% CHG with innovative, "hands-off" applicators to provide a more effective system for helping reduce infections associated with skin bacteria. ChloraPrep is fast-acting on a broad spectrum of bacteria, including MRSA, and inhibits bacterial growth for at least 48 hours.<sup>2,3</sup> **Help stop infection from the start with ChloraPrep.**

- **PERSISTENT** antimicrobial activity inhibits the growth of bacteria for at least 48 hours<sup>2,3</sup>
- **PROVEN** in 36 published studies as best practice for helping reduce the risk of infection
- **RECOMMENDED** use of 2% CHG formulation in at least 11 evidence-based guidelines, including the CDC, SCAI and IHI

**REFERENCES** 1. Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir of resident skin flora. *J Infect Dis.* 1989;160(4):644-650. 2. Garcia R, Mulberry G, Brady A, Hibbard JS. Comparison of ChloraPrep and Betadine as preoperative skin preparation antiseptics. Poster presented at 40th Annual Meeting of the Infectious Diseases Society of America, October 25, 2002, Chicago, Ill. 3. Data on file. Cardinal Health, Inc.



**ChloraPrep®**

Patient Preoperative Skin Preparation  
2% Chlorhexidine Gluconate (CHG)  
& 70% Isopropyl Alcohol (IPA)

chloraprep.com | 800-523-0502

©2009 Cardinal Health, Inc. All rights reserved. ChloraPrep is a registered trademark of Cardinal Health, Inc. or one of its subsidiaries. ADV-SBC0309



# THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

Infection prevention and control in healthcare settings is a critical public health problem rapidly gaining interest.

**Are you current with the latest trends and evidence?**

**Join SHEA Today!**

Stay on top of emerging science and evidence-based strategies to prevent and control infections and to improve quality-of-care in your healthcare facility.

SHEA supports members' efforts to improve patient care and healthcare worker safety through:

- Research
- Education & Training
- Policy Development
- Evidence-based Practical Guidelines
- Mentorship and Professional Development

### **Application Details**

[www.shea-online.org](http://www.shea-online.org)  
[info@shea-online.org](mailto:info@shea-online.org)  
(703) 684-1006


Annual membership offers:

- Subscription and online access to *Infection Control and Hospital Epidemiology (ICHE)*, the official journal of SHEA
- Epidemiology News and e-newsletter
- Discounted registration on SHEA educational programming
- Online member network and job board



*The Society for Healthcare Epidemiology of America*





All five senses  
say it's clean.

What does your  
sixth say?

**Trust your instincts** and your hospital to Ecolab Healthcare. Our comprehensive infection prevention solutions help you protect your patients, your staff and your hospital's reputation with confidence.

Call 866.781.8787 or visit [Ecolab.com/healthcare](http://Ecolab.com/healthcare).

Leave nothing at risk with the right infection prevention partner.

**ECOLAB**<sup>®</sup>

HEALTHCARE





# INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

Keep current with the accelerating pace of infectious disease in clinical care facilities and how to improve upon that care. Order reprints in full color or black and white on high quality paper stock. Customize your reprint order with typesetting, logos, and covers.

Contact: Reprint Coordinator  
[reprints@press.uchicago.edu](mailto:reprints@press.uchicago.edu)  
773 702 7677 Voice  
773 702 0694 Fax



THE UNIVERSITY  
OF CHICAGO PRESS  
JOURNALS DIVISION  
[www.journals.uchicago.edu](http://www.journals.uchicago.edu)


# REPRINTS





## WHAT MAKES THE CLAVE DIFFERENT?

The CLAVE has been engineered with fail-safe features which help mitigate bacterial transfer into the patient's catheter.



# CLAVE<sup>®</sup> Connector Technology



Don't be fooled by the sales gimmicks, look to the evidence.

- CLAVE supported a statistically significant lower BSI rate compared to another connector. (*Moore, 2009*)
- CLAVE demonstrates the best barrier to bacterial transfer compared to all connectors. (*Ryder, 2007*)
- CLAVE was proven to support a lower occurrence of bloodstream infections when compared to a positive pressure device. (*Maragakis, 2006*)
- CLAVE showed a lower occurrence of intraluminal catheter colonization in a randomized clinical trial. (*Bouza, 2003*)



# IDS A

47<sup>th</sup> Annual Meeting

Oct. 29 - Nov. 1, 2009  
Philadelphia, PA

For details on:

- Important Dates
- Preliminary Program
- Registration and Housing Online

Please visit [www.idsociety.org/meetings](http://www.idsociety.org/meetings)



# IDS A

Infectious Diseases Society of America

# hivma

hiv medicine association




# FIND THE MICROBE THAT COULD COST THIS PATIENT HER LIFE.

80% of the bacteria that cause infections reside in the first five layers of the patient's own skin.<sup>1</sup> That's why there's ChloroPrep®. ChloroPrep combines the CDC-recommended formulation of 2% CHG with innovative, "hands-off" applicators to provide a more effective system for helping reduce infections associated with skin bacteria. ChloroPrep is fast-acting on a broad spectrum of bacteria, including MRSA, and inhibits bacterial growth for at least 48 hours.<sup>2,3</sup> **Help stop infection from the start with ChloroPrep.**

- **PERSISTENT** antimicrobial activity inhibits the growth of bacteria for at least 48 hours<sup>2,3</sup>
- **PROVEN** in 36 published studies as best practice for helping reduce the risk of infection
- **RECOMMENDED** use of 2% CHG formulation in at least 11 evidence-based guidelines, including the CDC, SCAI and IHI

REFERENCES 1. Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir of resident skin flora. *J Infect Dis*. 1989;160(4):644-650. 2. Garcia R, Mulberry G, Brady A, Hibbard JS. Comparison of ChloroPrep and Betadine as preoperative skin preparation antiseptics. Poster presented at 40th Annual Meeting of the Infectious Diseases Society of America; October 25, 2002; Chicago, Ill. 3. Data on file. Cardinal Health, Inc.



chloroprep.com | 800-523-0502

©2009 Cardinal Health, Inc. All rights reserved. ChloroPrep is a registered trademark of Cardinal Health, Inc. or one of its subsidiaries. ADV-SBC0309





Call 1-800-323-2220  
for a free sample.

# NO UR

## CHG formula doesn't go down the drain.

### Chlorhexidine Gluconate (CHG) No-Rinse Cloths: STAYS ON YOUR PATIENTS' SKIN TO FIGHT MDROs

They achieve compliance to your SSI prevention protocol  
and mirror current clinical guidelines:

**“To gain the maximum antiseptic effect of chlorhexidine, it  
must be allowed to dry completely and not be washed off.”<sup>1</sup>**

—SHEA *Compendium of Strategies To Prevent Healthcare-Associated  
Infection in Acute Care Hospitals*

**“Patients undergoing open class I surgical  
procedures below the chin should have two (2)  
preoperative showers with chlorhexidine gluconate  
(CHG) before surgery, when appropriate.”<sup>2</sup>**

—AORN *Guidelines for Preoperative Skin Antisepsis*



### Proven results

One facility saw a 66% reduction in SSIs and a  
cost avoidance of \$349,000 over a 10-month  
period when using Sage 2% CHG Cloths.<sup>3</sup>

📞 Call 1-800-323-2220 for a free sample.



[www.sageproducts.com/CHG](http://www.sageproducts.com/CHG)

1. SHEA, Oct 2008, Vol. 29, Supplement 1, S58. 2. Perioperative Standards and Recommended Practices, AORN, Inc., 2008, 537-555. 3. Rhee H, Harris B. Preoperative Skin Preparation Protocol Results in Reduced SSI Rates, Institute for Healthcare Improvement (IHI), Orlando, FL, December 2007.